Literature DB >> 27463977

One year in review 2016: systemic lupus erythematosus.

Antonella Adinolfi1, Eleonora Valentini2, Emanuele Calabresi3, Giulia Tesei4, Viola Signorini3, Simone Barsotti5, Chiara Tani3.   

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a highly variable course and prognosis. The management of the disease is still a clinical challenge for the treating physicians as many aspects regarding the disease pathogenesis, clinical picture and outcomes remain to be elucidated. New and interesting data are emerging; here the recent literature on SLE pathogenesis, clinical and laboratory aspects, as well as treatments and comorbidities, are reviewed and the main findings summarised in order to provide a bird's eye on the relevant papers on these topics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27463977

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.

Authors:  Zi-Wei Dai; Hong Wang; Wen-Juan Xu; Zhi-Hui Wang; Sheng-Qian Xu; Bin Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-07-06       Impact factor: 2.980

Review 2.  Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review.

Authors:  Lorena Flor da Rosa Franchi Santos; Neide Tomimura Costa; Michael Maes; Andréa Name Colado Simão; Isaias Dichi
Journal:  Inflammopharmacology       Date:  2019-12-09       Impact factor: 4.473

3.  Serum level of fetuin-A in systemic lupus erythematosus patients: association with atherosclerosis and disease activity.

Authors:  Doaa Salah Atta; Ahmed Emera; Rana S Ghoneim; Amina M Elnaggar
Journal:  Clin Rheumatol       Date:  2021-01-07       Impact factor: 2.980

4.  Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia.

Authors:  Qian Sun; Li Wang; Hua-Yuan Zhu; Yi Miao; Wei Wu; Jin-Hua Liang; Lei Cao; Yi Xia; Jia-Zhu Wu; Yan Wang; Rong Wang; Lei Fan; Wei Xu; Jian-Yong Li
Journal:  Chin Med J (Engl)       Date:  2019-03-05       Impact factor: 2.628

5.  3-hydroxy butyrate dehydrogenase 2 deficiency aggravates systemic lupus erythematosus progression in a mouse model by promoting CD40 ligand demethylation.

Authors:  Bo Yang; Shihao Hou; Jingjing Zhao; Yepeng Li
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

6.  Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

Authors:  Herbert Struemper; Mita Thapar; David Roth
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.